PDF Print E-mail

hologic

Since their beginnings in 1986, Hologic have pioneered DEXA. Hologic invented the technique, were the first to develop fan beam technology and are the current world leaders. In addition, Hologic have branched out and manufacture the Hologic Fluoroscan InSight mini C arm. Building upon this success, Hologic are now the worlds No1 womens health company. Vertec is proud to have been the very first overseas distributor for Hologic and have been a part of this success.

Hologic products represented by Vertec are:


Discovery  - Flagship of the Hologic DEXA range, The Hologic Discovery, a QDR series bone densitometer, combines the proven clinical value of Bone Mineral Density  (BMD) measurement and vertebral assessment with Express BMD.


Explorer  - Designed by Hologic to meet the needs of customers on a tight budget, The Explorer is Hologic's newest bone densitometer. Explorer features many of Hologic's innovative options.


Sahara - developed by Hologic to provide bone density testing capabilities to your private practice or clinic with the portable, waterless, easy-to-use Sahara Clinical Bone Ultrasonometer.


OnePass fan beam technology  - Hologic introduced the first fan-beam densitometer in 1992. This revolution in technology has resulted in higher resolution and shorter scan times, while maintaining excellent precision.


Instant Vertebral Assessment (IVA) - Poineered by Hologic with their early fan-beam systems, IVA enables clinicians to perform a rapid, low-dose evaluation of vertebrae in a single office visit, during a routine bone density exam.


IRIS - Hologic recognise the need for Connectivity Solutions for bone densitometry systems to help operators and physicians streamline workflow between and within facilities and workstations.

Upgrades your Hologic QDR 4500 or Hologic Delphi to a Hologic Discovery system and Discover the Difference Ten Seconds Make.


Fluroscan Premier Encore and InSight Mini C-arm's - Completely re-designed by Hologic, The InSight is designed to improve efficiency and quality in extremity surgery.
 

News Login






Forgot login?
No account yet? Register

Vertec News

Calypso at the Royal Marsden
 Pictured following the recent handover of a Calypso patient movement tracking system to the Radiotherapy Group at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (ICR) in Sutton, Surrey, are (from left): Vertec sales specialist Nikki Mara, clinical oncologists Professor David Dearnaley and Dr Gerard McVey, physicist Dr Philip Evans, research radiographer Ms Helen McNair and physicists Dr Anthony Kavanagh and Dr Westley Ingram.This installation of Calypso is the first in UK. The system uses a transmitter centred feedback circuit to advise when the target is out of alignment with the treatment beam so that corrective action can be taken. The advantage for this is that dose delivery given to the target is optimised. According to Dr Evans: “Uniquely, the Calypso system uses implanted transponders to measure set-up accuracy during radiotherapy so there is zero radiation dose and set-up accuracy can be measured continuously and more rapidly than alternative systems." The Royal Marsden opened its doors in 1851 as the world’s first hospital dedicated to cancer treatment, research and education. It is a centre of excellence, and the only NHS Trust to achieve the highest possible ranking in the Healthcare Commission’s Annual Health Check for the fourth year in a row. The ICR is one of the world's leading cancer research organisations and is internationally renowned for the quality of its science. It has been ranked the UK’s top academic research centre, based on the results of the Higher Education Funding Council’s Research Assessment ExerciseTogether, the two organisations form the largest and most comprehensive cancer centre in Europe treating over 40,000 patients every year.  Comments Vertec’s Nikki Mara, “We are very pleased that the first Calypso in the UK is here at The Royal Marsden and The Institute of Cancer Research as it is a world centre for clinical excellence in the treatment of cancer patients.”